Der Erlös wird verwendet, um die klinische Entwicklung des besten und ersten neutralisierenden Antikörpers seiner Klasse, MTX-005, gegen BK-Virus-Infektionen bei Nierentransplantationspatienten durch die Phase 2 der klinischen Entwicklung zu bringen. Darüber hinaus werden die Mittel zur Entwicklung und Erweiterung der Antikörper-Pipeline und zur Sicherung neuer Partnerschaftsvereinbarungen verwendet.
Memo Therapeutics erhielt kürzlich eine Zusage in Höhe von 10,5 Mio. CHF vom Schweizer Bundesförderprogramm für COVID-19-Arzneimittel, um COVAB 36, einen potenten, vollständig humanen monoklonalen Antikörper, der zur Behandlung von SARS-CoV-2-Infektionen durch Inhalation verabreicht wird, in die klinische Entwicklung zu bringen.
Team von BGPartner
Das Team wurde von Oliver Gnehm (Partner) geleitet und bestand aus Victoria Marty (Associate) und Thomas Gysin (Senior Associate).
Team von Walder Wyss
Das Team von Walder Wyss wurde von Partner Alexander Gutmans (Gesellschaftsrecht und Risikokapital) geleitet und umfasste Senior Associate Michelle Bruni (Gesellschaftsrecht und Steuerrecht), Associate Karina Tschon (Gesellschaftsrecht und Risikokapital) und Associate Bojan Momic (Gesellschaftsrecht und Arbeitsrecht).
Informationen von Memo Therapeutics AG über die Transaktion
Die Memo Therapeutics AG informierte wie folgt über die Transaktion:
Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today the close of an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from a combination of strategic and financial investors, including Adjuvant Capital, Fresenius Medical Care Ventures, GF Group, Verve Ventures, Vesalius Biocapital and Zürcher Kantonalbank.
The proceeds will be used to advance clinical development of its best- and first-in-class neutralizing antibody, MTX-005, targeting BK virus infection in renal transplant patients through Phase 2 clinical development. BK virus infection poses a high and unmet medical need to transplant success and presents a large (more than USD1 billion) and growing market (more than 15% p.a.) opportunity. In addition, MTx will use the funding to develop and expand its antibody pipeline and secure new partnering agreements.
“We are extremely impressed with the power of Memo Therapeutics AG’s antibody technologies, which provide best-in-class B-cell repertoire coverage from any donor species and single-cell-based high-throughput functional screening capabilities, which enable direct analysis of millions of candidate antibodies,” said Dr. Andreas Wüpper, Director of Investments at Fresenius Medical Care Ventures. “We believe this approach is applicable to many therapeutic areas and look forward to seeing the results from clinical evaluation of the BK virus program.”
“Our unique approach to discover and develop novel therapeutic antibodies continues to generate impressive data. This progress has resonated with highly renowned strategic and financial investors, who we are happy to welcome in this oversubscribed extension of our Series B,” said Dr. Karsten Fischer, Chief Executive Officer of Memo Therapeutics AG. “This funding, together with the recent Swiss Federal government COVID-19 grant, will enable us to advance our two lead programs, MTX-005 and COVAB 36, into clinical development this year and to develop and expand our antibody pipeline, which includes cytomegalovirus (CMV) and Nipah virus.”
As part of the financing round, Dr. Andreas Wüpper, Director of Investments at Fresenius Medical Care Ventures, Dr. Christian Schneider, Managing Partner at Vesalius Biocapital and Dr. Philippe Dro, Partner at Adjuvant Capital will join the MTx Board of Directors.
